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PURPOSE. To determine the disease course of retinal dystrophy caused by recessive variants in
the DRAM2 (damage-regulated autophagy modulator 2) gene.
METHODS. Sixteen individuals with DRAM2-retinopathy were examined (six families; age
range, 19–56 years, includes one pre-symptomatic case). The change in visual acuity over time
was studied, and electrophysiology (n ¼ 6), retina-tracking perimetry (n ¼ 1), fundus
autofluorescence (FAF) imaging (n ¼ 6), and optical coherence tomography (OCT; n ¼ 12)
were performed.
RESULTS. All symptomatic patients presented with central visual loss (15/15) unaccompanied
either by nyctalopia or light-hypersensitivity; most (11/15) developed symptoms in the third
decade of life. A granular macular appearance, often with associated white/yellow dots, was
an early fundoscopic feature. There was an ill-defined ring of hyperautofluorescence on FAF.
Optical coherence tomography revealed loss of the ellipsoid zone perifoveally in a 19-year-old
pre-symptomatic individual. The central atrophic area enlarged over time and fundoscopy
showed peripheral degeneration in seven of the nine individuals that were examined ‡10
years after becoming symptomatic; some of these subjects developed nyctalopia and light
hypersensitivity. Electrophysiology revealed generalized retinal dysfunction in three of the
five individuals that were tested ‡10 years after becoming symptomatic.
CONCLUSIONS. Patients with DRAM2-retinopathy are typically asymptomatic in the first two
decades of life and present with central visual loss and a maculopathy. A faint
hyperautofluorescent ring on FAF can be a suggestive feature. The retinal periphery is
frequently affected later in the disease process. Photoreceptor degeneration is likely to be the
primary event and future studies on DRAM2-retinopathy are expected to provide important
insights into retinal autophagy.
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Genetic testing for retinal dystrophies has been revolution-ized by the advent of high-throughput sequencing
approaches such as multigene panel testing, exome sequenc-
ing, and genome sequencing.1–3 As the results of genetic
testing are increasingly being used in medical decision-making
(e.g., genetic risk assessment and identification of subjects who
would benefit from gene-based therapies), misinterpretation of
variants can have important consequences for patients.4 A
comprehensive understanding of the natural history and
phenotypic variability associated with each genetic disease
subtype can often help avoid such misinterpretations. To
achieve this, it is key to pool patient cohorts from multiple
centers and to report clinical data to the fullest possible extent.
The focus of this study is DRAM2, a gene recently associated
with autosomal recessive retinal dystrophy.5 Affected individ-
uals from five families have been previously described; early
macular involvement and, in some cases, panretinal degener-
ation was observed.5
The gene DRAM2 [MIM 613360] encodes a 266–amino acid
transmembrane protein with a role in autophagy induction.6
Autophagy is a recycling pathway for obsolete parts of cells
such as organelles and long-lived or misfolded proteins. It
involves delivering material to lysosomes for degradation and is
often upregulated in response to organelle damage or
metabolic stress.7,8 Dysregulation of autophagy has been
implicated in many disorders, including cancer and neurode-
generation.9,10 Its role in the visual system, and especially in
the photoreceptors and RPE, is currently an area of intense
investigation.11–13
DRAM2 is expressed in a number of tissues, including heart,
placenta and retina; the associated protein, like many other
autophagy regulator molecules, is localized in the lyso-
some.5,14,15 Immunofluorescence microscopy in murine reti-
nae revealed Dram2 staining in the photoreceptor inner
segments, where photoreceptor lysosomes are found, and in
the apical surface of the RPE.5
The present study details retinal structure and visual
function in a cohort of individuals with DRAM2-retinopathy,
many with long-term follow-up. Genetic findings in a
previously unreported case are also described.
SUBJECTS AND METHODS
Biallelic DRAM2 variants have previously been shown to be
disease-causing in one large consanguineous pedigree (family
ES1, 11 affected subjects) and four simplex cases (1325,
gc17004, gc4728 and BL1).5 All 15 affected individuals from
these five families participated in the present study. An
additional unrelated proband (subject PCI1) that was found
by exome sequencing to harbor a homozygous DRAM2 variant
was also included; exome sequencing was performed as
previously described (SureSelectXT Human All Exon V5
capture, Illumina HiSeq2000 sequencer; Agilent, Santa Clara,
CA, USA)16 and segregation analysis in parental samples was
conducted using Sanger sequencing. The Ghent University
Hospital, University Hospital Bonn, Moorfields Eye Hospital
and Leeds East Research Ethics Committees approved the study
and all investigations were conducted in accordance to the
tenets of the Declaration of Helsinki; informed consent was
obtained from all participating individuals.
Clinical assessment included best-corrected visual acuity
testing, dilated fundus examination, color fundus photography,
fundus autofluorescence (FAF) imaging, retina-tracking perim-
etry and optical coherence tomography (OCT). The Spectralis
HRA+OCT system (Heidelberg Engineering, Heidelberg, Ger-
many) was used to acquire FAF images (over a 308 3 308 and/or
a 558 3 558 field) in six unrelated subjects (age range, 25–46
years), and spectral-domain OCTs in nine subjects (age range,
19–46 years). A time-domain OCT system (Stratus OCT3; Carl
Zeiss Meditec, Dublin, CA, USA) was used to image one of
these patients plus three additional study subjects (age range,
24–47 years). The OCT protocol included volume scans
centered on the fovea in each case. Retinal imaging was
performed on more than one visit in six patients (intertest
intervals of 1–8 years).
Electrophysiological assessment was performed in six
unrelated subjects (age range, 29–47 years). The protocols
used incorporated the standards of the International Society of
Electrophysiology of Vision (ISCEV) for full-field and pattern
ERG (PERG).17,18 Longitudinal data were available in three
study subjects (intertest intervals of 4, 9, and 13 years).















IV:10 (ES1) M Asymptomatic (19) 19 0.0/0.0 p.[(Gly47Valfs*3)];[(Gly47Valfs*3)]
IV:7 (ES1) M Central visual loss (22) 23 0.2/0.2 p.[(Gly47Valfs*3)];[(Gly47Valfs*3)]
IV:9 (ES1) F Central visual loss (22) 25 1.0/1.0 p.[(Gly47Valfs*3)];[(Gly47Valfs*3)]
IV:8 (ES1) F Central visual loss (21) 24 0.8/0.8 p.[(Gly47Valfs*3)];[(Gly47Valfs*3)]
IV:11 (ES1) F Central visual loss (27) 29 1.0/1.0 p.[(Gly47Valfs*3)];[(Gly47Valfs*3)]
IV:6 (ES1) F Central visual loss (26) 32 0.8/0.8 p.[(Gly47Valfs*3)];[(Gly47Valfs*3)]
III:4 (ES1) M Central visual loss (23) 56 2.0/2.0 p.[(Gly47Valfs*3)];[(Gly47Valfs*3)]
III:13 (ES1) M Central visual loss (25) 46 2.0/2.0 p.[(Gly47Valfs*3)];[(Gly47Valfs*3)]
III:5 (ES1) F Central visual loss (28) 51 1.0/2.0 p.[(Gly47Valfs*3)];[(Gly47Valfs*3)]
III:6 (ES1) M Central visual loss (25) 37 1.3/1.3 p.[(Gly47Valfs*3)];[(Gly47Valfs*3)]
III:1 (ES1) M Central visual loss (16) 48 2.3/2.3 p.[(Gly47Valfs*3)];[(Gly47Valfs*3)]
1325 F Central visual loss (29) 47 1.0/1.0 p.[(Ser44Asn)];[(Trp165*)]
gc17004 F Central visual loss (29) 39 1.3/2.0 p.[(Tyr27His)];[(Val73_Tyr75del)]
gc4728 M Central visual loss (34) 47 1.3/1.3 p.[(His121Leu)];[(His121Leu)]
BL1 F Central visual loss (30) 44 1.0/1.0 p.[(Ala22del)];[(Ala22del)]
PCI1 F Central visual loss (35) 43 0.6/0.4 p.[(Gly57Arg)];[(Gly57Arg)]
As the disease progressed, subjects III:4, III:13, IV:9, IV:6, 1325, and PCI1 developed photophobia; subjects III:13 and 1325 also complained of
night vision problems. On fundoscopy, subjects III:4, III:13, III:5, III:1, 1325, gc17004, and gc4728 had both central and peripheral retinal changes
at last examination while IV:10 had an apparently normal fundus.
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FIGURE 1. Diagram illustrating the visual acuity in 16 subjects with DRAM2-retinopathy and how this changed over time. The mean logMAR visual
acuity between the right and left eye is plotted for each time point.
FIGURE 2. Color fundus photographs from five subjects with DRAM2-retinopathy. Images from the right eye of subject IV:8 at age 24 (A), subject
IV:11 at age 29 (B), subject IV:6 at age 32 (C), subject III:4 at age 56 (D; all from family ES1), and subject BL1 at age 44 (E) are shown. A granular
appearance with white/yellow dots in the central macula is present in (A–C) and (E). There is more widespread RPE irregularity and pigment
clumping in (C) and (D). All cases show a high degree of interocular symmetry.
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Retina-tracking mesopic perimetry (MAIA; CenterVue,
Padova, Italy) was performed in subject PCI1 following pupil
dilation. The examination was started after 20 minutes of
adaptation to the red test background luminance at 1.27 cd/
m2. A custom perimetric test pattern (foveopapillary profile)
examining 50 loci, mostly placed along the horizontal line
through the foveal center covering 308 of the central visual
field, was used. White test points (Goldmann III, 200 ms in
duration) were presented using a 4-2 staircase strategy.
Luminance of stimuli was scaled from 0 (318.5 cd/m2) to an
attenuation of 36 dB (0.1 cd/m2; measurement range, 3.6 log
units). Ceiling effects should be negligible as normal controls
revealed retinal light sensitivity of 29.7 6 1.14 dB in the
macular area (see manufacturer’s instructions available online
at http://www.accessdata.fda.gov/cdrh_docs/pdf9/K092187.
pdf). The patient was asked to maintain fixation on a red
central circle of 18 diameter at a preferred retinal locus. One
full perimetric test was performed with each eye before
examination was executed to reduce learning effects. The
inbuilt confocal scanning laser ophthalmoscope (830 nm)
creates an infrared image of 368 3 368 field of view of the
central retina, which is followed in real-time by a 25-Hz retinal
landmark eye tracker, assuring precise topographic correlation
between fundus details and light stimuli projection.
RESULTS
The clinical features of the 16 individuals with DRAM2-
retinopathy are summarized in the Table and Supplementary
Table S1. One study subject remained asymptomatic at age 19.
All other patients presented with reduced central vision. The
median age at onset for the cohort was 25 years (range, 16–35
years) with 11 of 15 patients becoming symptomatic in the
third decade of life (Table). Most affected individuals devel-
oped significant visual impairment within a few years from
presentation (Fig. 1). Three of the nine subjects that were seen
at least a decade after becoming symptomatic reported light
hypersensitivity; two of these subjects also reported difficulty
seeing in dim illumination. Fundoscopic findings are illustrated
in Figures 2, 3, and 4, and described in Supplementary Table
S1. A granular macular appearance was present early in the
disease. This was typically associated with fine white/yellow
dots and often evolved into a well-defined central atrophic
area. Peripheral bone-spicule pigmentation can develop later in
the disease process; seven of the nine subjects that were seen
at least a decade after becoming symptomatic developed
midperipheral and/or peripheral retinal changes. All patients
were phakic and none showed extraocular abnormalities
suggestive of syndromic retinal disease.
FIGURE 3. Color fundus photographs and FAF images from two unrelated individuals with DRAM2-retinopathy. (A) Subject gc17004: fundus
photography at age 38 (top row), FAF imaging at age 30 (middle row) and 38 (bottom row). (B) Subject gc4728: fundus photography at age 45 (top
row), FAF imaging at age 37 (middle row) and 45 (bottom row). Fundus autofluorescence imaging shows an area of decreased signal at the center
surrounded by a faint, hyperautofluorescent ring that enlarges and becomes less well-defined over time. Midperipheral areas of irregular signal were
also observed at the follow-up images of both study subjects (bottom row).
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Fundus autofluorescence imaging was performed in six
patients: subject IV:9 from family ES1 (images presented in Ref.
5) as well as subjects 1325, gc17004, gc4728, BL1, and PCI1.
All tested individuals had a central area of irregular signal
surrounded by a faint, ill-defined hyperautofluorescent ring
(Figs. 3, 4). Notably, FAF imaging data from follow-up visits in
three patients revealed progressive enlargement of the central
defect; peripheral retinal involvement was present in two of
these individuals (Fig. 3). Thinning of the hyporeflective band
corresponding to the outer nuclear layer was observed on OCT
imaging in 11 of 11 symptomatic individuals. Spectral domain
OCT in the pre-symptomatic 19-year-old subject IV:10 (family
ES1) revealed loss of the ellipsoid zone in a perifoveal area
(Supplementary Fig. S1A). Subject IV:9 had OCT imaging 1 year
before developing symptoms (age 21, using time-domain OCT)
and 3 years after becoming symptomatic (age 25, using spectral
domain OCT; data shown in Ref. 5). The central foveal
thickness (mean thickness within the central 1000 lm
diameter) in that subject was bilaterally reduced in the pre-
symptomatic phase (100 lm right, 115 lm left).
Electrophysiology was performed in one individual from
each family. Representative data are shown in Figure 5. Subject
III:6 from family ES1 was assessed at age 37 (12 years after
becoming symptomatic). He had normal full-field ERGs, but the
PERGs were severely subnormal in keeping with macular
dysfunction. Subject 1325 was also tested; full-field ERGs and
PERGs were undetectable at age 46 (17 years after becoming
symptomatic; data shown in Ref. 5). Both subjects gc17004 and
gc4728 were tested soon after presentation (ages 30 and 34
years, respectively) and showed PERG evidence of severe
macular dysfunction but normal full-field ERGs (Figs. 5A, 5C);
subject gc17004 also had an electro-oculogram which was
within normal limits. Both were retested 9 (for subject gc17004)
and 13 (for subject gc4728) years later (10 and 13 years after
becoming symptomatic). Full-field ERGs under both scotopic
and photopic conditions were subnormal with additional delay
in the flicker ERGs (Figs. 5B, 5D). Subject BL1 was tested at age
40 and 44 (10 and 14 years after becoming symptomatic): the
PERGs were severely attenuated in keeping with macular
dysfunction, but full-field ERGs were normal without evidence
of progression. Subject PCI1 was tested at age 42 (7 years after
becoming symptomatic) and was found to have normal full-field
ERGs under scotopic conditions; the amplitude of the photopic
ERG was borderline and there was no delay in the flicker ERG.
Retina-tracking perimetry findings from this individual are
shown in Figure 4. When the perimetry results were overlaid
with the FAF and OCT images, relatively preserved visual
function and retinal structure were noted outside the hyper-
autofluorescent ring, although a slight functional deficit and
thinning of the outer retina may be present.
The genetic data are summarized in the Table and
Supplementary Table S2. The previously unreported subject
PCI1, a female born to first cousin parents, was found to have a
homozygous c.169G>C, p.(Gly57Arg) variant in DRAM2. This
variant affects a glycine residue that is conserved from human
to nematode and was not present in publicly available datasets
(Exome Aggregation Consortium [ExAC] browser, NHLBI
Exome Sequencing Project Exome Variant Server [EVS], dbSNP
and 1000 Genomes Project database; all accessed June 22,
2015). In silico analysis using the SIFT (v1.03) and Polyphen-2
(v2.2.2r398) tools (both accessed June 22, 2015) predicted the
change to be pathogenic (SIFT score of 0.0 and HumVar score
of 1.0). She was the only affected family member and had two
unaffected siblings and two unaffected children. Both her
parents were heterozygotes for the c.169G>C change and
when the exome sequencing data were inspected, no
putatively disease-causing variants were detected in any other
retinal dystrophy associated gene.
Robust genotype-phenotype correlations cannot be drawn as
this is the first report detailing clinical findings in this molecular
subtype of retinal dystrophy. However, it may be significant that
affected individuals harboring at least one presumed loss-of-
function variant in DRAM2 (affected subjects from family ES1
and subject 1325) appear to manifest first symptoms earlier than
patients harboring only missense changes or in-frame deletions.
Subjects gc17004, gc4728, BL1 and PCI1, who fall in the latter
category, became symptomatic at a later age than other subjects
in the cohort. However, it cannot be excluded that this could in
part be due to case ascertainment bias.
Intrafamilial variability was observed in family ES1 where
the age of disease onset ranged from 16 to 28 years. Affected
family members can be split into two groups: the five siblings
IV:7, IV:8, IV:9, IV:10 and IV:11 (age range, 23–32 years), and
their uncles and parents (III:1, III:4, III:5, III:6, III:13; age
range, 37–56 years). In the sibling group, fundus appearance
was consistent with a macular dystrophy and only the eldest
member of the group (subject IV:6) had midperipheral
changes at age 32 (Fig. 2C). In the older group, significant
FIGURE 4. Color fundus photography (A), FAF imaging ([B] and top
row of [C]), optical coherence tomography (bottom row of [C]), and
retina-tracking perimetry (overlay in top row of [C]) in a 43-year-old
individual with DRAM2-retinopathy (subject PCI1). There was a high
degree of interocular symmetry and data from the right eye are only
shown. In order to study the nature of the observed hyperautofluor-
escent ring, the FAF and OCT images were overlaid with the perimetry
results (C). There was severe loss of retinal sensitivity over the central
area of reduced FAF with less severe losses over a concentric parafoveal
area; slightly eccentric to this, sensitivity was normal or relatively
preserved over the narrow ring of increased FAF signal. Best corrected
visual acuity was 0.6 logMAR and the preferred retinal locus was
located about 58 superior to the foveal center. Complete disruption of
the ellipsoid zone (corresponding to the photoreceptor outer
segments) is noted at the outer/anterior border of the ring. The
perimetry decibel scale is color-coded according to the manufacturer’s
normative studies with green representing normal values, yellow
suspect, red abnormal, and black scotoma.
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central and peripheral retinal involvement was observed in
subjects III:4 (age 56; Fig. 2D), III:13 (age 46), and III:1 (age
48; see Ref. 5). In contrast, subject III:6 had a healthy looking
peripheral retina and preserved full-field electroretinograms
at age 37, and subject III:5 had only subtle peripheral retinal
changes at age 51. The latter individual developed symptoms
at a later age and his retinopathy appears milder compared
with other affected family members of similar age (subjects
III:1, III:13, III:4).
DISCUSSION
Recessive variants in DRAM2, an autophagy regulator gene,
have been recently identified as a cause of retinal dystrophy
with early macular involvement.5 Although limited imaging
data have been previously presented,5 the phenotypic variabil-
ity and natural history of the disorder have not been described
in detail. A combination of longitudinal and cross-sectional data
from 16 affected individuals is reported here, providing
important insights into DRAM2-retinopathy.
Patients typically become symptomatic in the third decade
of life, describing increasing difficulty with close visual tasks.
Light hypersensitivity and night-blindness are not significant
early symptoms but they may be associated with advanced
disease. Fundus examination at early disease stages typically
reveals a granular appearance in the central macula, often with
associated fine white/yellow dots. Fundus autofluorescence
imaging shows a central area of abnormal signal surrounded by
a faint perifoveal hyperautofluorescent ring; associated chang-
FIGURE 5. Full-field and PERGs in subject gc17004 at age 30 (A) and 39 (B) and in subject gc4728 at age 34 (C) and 47 (D); a representative normal
set of traces is also shown for comparison (E). Both subjects showed a high degree of interocular symmetry and data from only one eye are shown.
Dark-adapted ERGs are shown for flash strengths of 0.01 and 10.0 cd.s/m2 (DA 0.01; DA 10.0). Light-adapted recordings are shown for a flash
strength of 3.0 cd.s/m2 (LA 3.0 and LA 30 Hz). Horizontal lines replace eye movement/blink artefacts. Initially (A, C), full-field ERGs show no
abnormality, but the PERG is severely reduced (A) or undetectable (C) in keeping with macular dysfunction. There is marked deterioration of both
rod and cone-derived ERGs at follow-up (B, D).
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es are observed on OCT. Enlargement of the central atrophic
area and, frequently, peripheral retinal involvement occur over
time. Electrophysiology confirms that dysfunction is initially
confined to the macula, but three of the five subjects that were
tested at least a decade after becoming symptomatic, had
developed full-field ERG abnormalities consistent with gener-
alized dysfunction involving both rods and cones.
A similar but not identical pattern of visual loss has been
previously reported in other retinal dystrophy subtypes.
Progressive macular atrophy surrounded by a ring of hyper-
autofluorescence has been described in individuals with
dominant variants in CRX [MIM 602225], PRPH2 [MIM
179605], GUCY2D [MIM 600179], RIMS1 [MIM 606629] and
PROM1 [MIM 604365]; X-linked variants in RPGR [MIM
312610]; and recessive variants in CDH3 [MIM 114021], TTLL5
[MIM 612268], KCNV2 [MIM 607604], and ABCA4 [MIM
601691].19,20 The lack of light hypersensitivity and night-
blindness at presentation can be a useful distinguishing feature.
ABCA4-retinopathy21 is perhaps the molecular subtype with
the closest resemblance to DRAM2-related disease. The pattern
of electroretinographic progression can be similar as one-fifth
of patients with ABCA4-retinopathy and normal full-field ERGs
at presentation, develop generalized retinal dysfunction over a
decade.22 The absence of retinal flecks is uncommon in
ABCA4-retinopathy but can occur.
Dram2 is expressed both in photoreceptor and RPE cells
and the location of the primary insult in DRAM2-retinopathy is
unclear.5 Optical coherence tomography data (Supplementary
Fig. S1A) suggest loss of photoreceptor outer segments early in
the disease process and support a primary photoreceptor
etiology. That is also in keeping with the FAF and perimetry
data. It can be speculated that the hyperautofluorescent ring is
associated with reduced absorption of light in a zone of retina
where outer segments are absent, and RPE fluorescence is
otherwise normal. This would explain the OCT finding of an
absent ellipsoid zone over the ring and an intact ellipsoid zone
outside the ring. A similar mechanism has been proposed for
the hyperautofluorescent ring observed in MYO7A-related
retinitis pigmentosa.23 Despite these observations, photore-
ceptor degeneration secondary to loss of RPE support cannot
be excluded. Notably, autophagy within the RPE has been
shown to contribute to both photoreceptor outer segment
degradation and visual cycle chromophore regeneration.24
Quantitative FAF imaging25 in subjects with DRAM2-retinopa-
thy and imaging of autophagic activity26 in experimental
models of DRAM2-related disease are expected to provide
further insights.
Although the exact role of DRAM2 remains to be
determined, previous work has suggested that it acts as a
positive regulator of autophagy.6 It is of interest that
hydroxychloroquine, an autophagy inhibitor widely prescribed
in the treatment of autoimmune diseases such as systemic
lupus erythematosus, can be associated with retinal toxici-
ty.27,28 In particular, the early OCT findings of DRAM2-
retinopathy (central retinal thinning and loss of the ellipsoid
zone in the perifoveal area), are reminiscent of frequent
observations in hydroxychloroquine toxicity.29 A number of
drugs with the capacity to induce autophagy have also been
reported including rapamycin (also known as sirolimus),
intravitreal administration of which has been attempted in
subjects with age-related macular degeneration and posterior
uveitis.30,31 The role of these agents in DRAM2-retinopathy
remains to be determined.
To conclude, this study details the clinical features of
DRAM2-retinopathy and illustrates the natural history of
photoreceptor loss in this disorder. Genetic data on a
previously unreported case are described and the clinical
utility of FAF imaging is demonstrated. The data presented have
the potential to improve counseling on disease prognosis, to
facilitate the identification of further individuals with this
molecular diagnosis and to guide future therapeutic interven-
tions.
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